The Forvis Mazars team played a critical role in managing and facilitating the successful sale of MediPharm Labs. Throughout the entire transaction the Forvis Mazars team acted as our trusted advisor and became an extension of the MediPharm team, they were agile and effective in dealing with various stakeholders (internally and externally) across international time zones and walked alongside us every step of the way. We found the Forvis Mazars team to be incredibly responsive and committed to a successful outcome. We were very happy with the support and services provided.
Mr Greg Hunter, Chief Financial Officer MediPharm Labs Inc.
MediPharm Labs Inc. - Case study
Lead M&A advisor for significant pharmaceutical provider - MediPharm Labs Inc.
Client
MediPharm Labs Australia Pty Ltd is the Australian subsidiary of the Canadian parent entity, MediPharm Labs Inc - a full service pharmaceutical company specialising in delivering high quality, innovative cannabis concentrate-based products and services.
Need
Our clients parent entity identified significant potential savings in moving all domestic and international manufacturing to the Canadian facility. This included the Australian facility, specialised licencing, operating knowledge, and selected customers in Australia and New Zealand currently served by the purpose-built facility in Wonthaggi, located in Victoria, Australia.
They appointed Forvis Mazars Financial Advisory team as corporate advisor.
The transaction required an experienced M&A Team to negotiate with several potential purchasers, facilitate the short listing of suitable parties and negotiate an optimal outcome.
Due to the international time differences associated with the location of our clients’ Executive Team, the transaction required intensive project management by Forvis Mazars, our clients international and local teams and the acquirers.
Results
After an extensive sale process where the Forvis Mazars team acted as lead corporate advisor for MediPharm, an agreement with One Life Botanicals (the joint venture Partner of Wellnex Life), was identified as a strategic fit for both parties. The resultant share sale agreement provided the client with 10M AUD inclusive of the share sale proceeds and assets retained by our client.